Insider · CIK 0001553594

Fishman Corey N.

Reports to the SEC for 4 companies · MORRISTOWN, NJ

sec.gov

Transactions

Companies

Filings

CIK

0001553594

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-08-06	ITRMIterum Therapeutics plc · Warrants (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+82.6K sh	—	—	82,613
2024-08-06	ITRMIterum Therapeutics plcM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+82.6K sh	—	—	137,062
2024-08-06	ITRMIterum Therapeutics plc · Subscription Rights (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−165K sh	—	—	0
2024-08-06	ITRMIterum Therapeutics plc · Warrants (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+82.6K sh	—	—	82,613
2023-11-20	ITRMIterum Therapeutics plcP Purchase	Director, Chief Executive Officer	PPurchase	+10K sh	$1.59	+$15.9K	54,449
2023-03-31	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+275K sh	—	—	275,000
2023-03-11	ITRMIterum Therapeutics plcA Award	Director, Chief Executive Officer	AAward	+14.3K sh	—	—	50,132
2023-03-11	ITRMIterum Therapeutics plc · Restricted Share UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−14.3K sh	—	—	0
2023-03-11	ITRMIterum Therapeutics plcF Tax Payment	Director, Chief Executive Officer	FTax Payment	−5,683 sh	$0.96	−$5,455.68	44,449
2022-03-11	ITRMIterum Therapeutics plc · Restricted Share UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−215K sh	—	—	215,000
2022-03-11	ITRMIterum Therapeutics plcM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+215K sh	—	—	537,008
2021-06-23	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+5.28M sh	—	—	5,280,000
2021-03-11	ITRMIterum Therapeutics plc · Restricted Share UnitsA Award	Director, Chief Executive Officer	AAward	+430K sh	—	—	430,000
2021-01-26	ITRMIterum Therapeutics plcS Sale	Director, Chief Executive Officer	SSale	−85.4K sh	$1.73	−$148K	322,008
2021-01-25	ITRMIterum Therapeutics plcA Award	Director, Chief Executive Officer	AAward	+168K sh	—	—	407,453
2020-12-02	BIOSPECIFICS TECHNOLOGIES CORPD Disposition to Issuer	Director	DDisposition to Issuer	−2,018 sh	—	—	0
2020-12-02	BIOSPECIFICS TECHNOLOGIES CORPStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,000 sh	$32.87	−$197K	0
2020-05-01	BIOSPECIFICS TECHNOLOGIES CORPStock Option (Right to Buy)A Award	Director	AAward	+6,000 sh	—	—	6,000
2020-04-13	BIOSPECIFICS TECHNOLOGIES CORPA Award	Director	AAward	+2,018 sh	—	—	2,018
2019-06-20	MOMENTA PHARMACEUTICALS INCRestricted Stock UnitM Exercise/Conversion	Director	MExercise/Conversion	−4,356 sh	—	—	0
2019-06-20	MOMENTA PHARMACEUTICALS INCM Exercise/Conversion	Director	MExercise/Conversion	+4,356 sh	—	—	10,090
2019-06-19	MOMENTA PHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director	AAward	+25K sh	—	—	25,000
2019-02-15	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+150K sh	—	—	150,000
2018-08-17	ITRMIterum Therapeutics plcP Purchase	Director, Chief Executive Officer	PPurchase	+2,000 sh	$8.73	+$17.5K	239,953
2018-06-20	MOMENTA PHARMACEUTICALS INCRestricted Stock UnitsA Award	Director	AAward	+4,356 sh	—	—	4,356
2018-06-20	MOMENTA PHARMACEUTICALS INCRestricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−5,734 sh	—	—	0
2018-06-20	MOMENTA PHARMACEUTICALS INCM Exercise/Conversion	Director	MExercise/Conversion	+5,734 sh	—	—	5,734
2018-06-20	MOMENTA PHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director	AAward	+8,855 sh	—	—	8,855
2018-05-30	ITRMIterum Therapeutics plc · Series A Preferred SharesC Conversion	Director, Chief Executive Officer	CConversion	−33.3K sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plc · Series B-1 Preferred SharesC Conversion	Director, Chief Executive Officer	CConversion	−4,050 sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plc · Series B-2 Preferred SharesC Conversion	Director, Chief Executive Officer	CConversion	−1,591 sh	—	—	0
2018-05-30	ITRMIterum Therapeutics plcP Purchase	Director, Chief Executive Officer	PPurchase	+3,000 sh	$13.00	+$39K	237,953
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Director, Chief Executive Officer	CConversion	+1,591 sh	—	—	234,953
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Director, Chief Executive Officer	CConversion	+4,050 sh	—	—	233,362
2018-05-30	ITRMIterum Therapeutics plcC Conversion	Director, Chief Executive Officer	CConversion	+33.3K sh	—	—	229,312
2018-05-24	ITRMIterum Therapeutics plc · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+127K sh	—	—	127,307
2017-06-20	MOMENTA PHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director	AAward	+11.2K sh	—	—	11,207
2017-06-20	MOMENTA PHARMACEUTICALS INCRestricted Stock UnitsA Award	Director	AAward	+5,734 sh	—	—	5,734
2016-09-22	MOMENTA PHARMACEUTICALS INCStock Option (Right to Buy)A Award	Director	AAward	+33K sh	—	—	33,000
2014-11-17	Durata Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	CFO&COO	DDisposition to Issuer	−110K sh	—	—	0
2014-11-17	Durata Therapeutics, Inc.D Disposition to Issuer	CFO&COO	DDisposition to Issuer	−24.9K sh	—	—	0
2014-11-17	Durata Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	CFO&COO	DDisposition to Issuer	−219K sh	—	—	0
2014-11-17	Durata Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	CFO&COO	DDisposition to Issuer	−21.6K sh	—	—	0
2014-11-17	Durata Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	CFO&COO	DDisposition to Issuer	−12.5K sh	—	—	0
2014-11-17	Durata Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	CFO&COO	DDisposition to Issuer	−50K sh	—	—	0
2013-02-12	Durata Therapeutics, Inc.Stock Option (right to buy)A Award	CFO&COO	AAward	+50K sh	$7.49	+$375K	302,824
2012-07-24	Durata Therapeutics, Inc.Series A Convertible Preferred StockC Conversion	CFO&COO	CConversion	−180K sh	—	—	0
2012-07-24	Durata Therapeutics, Inc.C Conversion	CFO&COO	CConversion	+22.4K sh	—	—	22,441
2012-07-24	Durata Therapeutics, Inc.P Purchase	CFO&COO	PPurchase	+2,500 sh	$9.00	+$22.5K	24,941
2012-03-15	Durata Therapeutics, Inc.Series A Convertible Preferred StockP Purchase	CFO&COO	PPurchase	+51.2K sh	$1.00	+$51.2K	179,531

Recent filings

Accepted (ET)
Aug 124
Fishman Corey N.0000950170-24-095095
SEC(opens sec.gov)
Nov 204
Fishman Corey N.0001209191-23-056092
SEC(opens sec.gov)
Apr 34
Fishman Corey N.0001209191-23-022420
SEC(opens sec.gov)
Mar 144
Fishman Corey N.0001209191-23-018584
SEC(opens sec.gov)
Mar 154
Fishman Corey N.0001209191-22-018861
SEC(opens sec.gov)
Jun 254
Fishman Corey N.0000899243-21-025956
SEC(opens sec.gov)
Mar 154
Fishman Corey N.0000899243-21-011583
SEC(opens sec.gov)
Jan 274
Fishman Corey N.0000899243-21-003521
SEC(opens sec.gov)
Dec 24
Fishman Corey N.0000899243-20-032455
SEC(opens sec.gov)
May 44
Fishman Corey N.0000899243-20-011919
SEC(opens sec.gov)
Apr 154
Fishman Corey N.0000899243-20-010760
SEC(opens sec.gov)
Jun 214
Fishman Corey N.0001179110-19-008025
SEC(opens sec.gov)

Companies

Address

C/O DURATA THERAPEUTICS, INC. 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR

MORRISTOWN, NJ, 07960